Prevention of clinical and histological signs of proteolipid protein (PLP)-induced experimental allergic encephalomyelitis (EAE) in mice by the water-soluble carbon monoxide-releasing molecule (CORM)-A1

Research output: Contribution to journalArticlepeer-review

51 Citations (Scopus)


We have evaluated the effects of the carbon monoxide-releasing molecule CORM-A1 [Na-2(BH3CO2); ALF421] on the development of relapsing-remitting experimental allergic encephalomyelitis (EAE) in SJL mice, an established model of multiple sclerosis (MS). The data show that the prolonged prophylactic administration of CORM-A1 improves the clinical and histopathological signs of EAE, as shown by a reduced cumulative score, shorter duration and a lower cumulative incidence of the disease as well as milder inflammatory infiltrations of the spinal cords. This study suggests that the use of CORM-A1 might represent a novel therapeutic strategy for the treatment of multiple sclerosis.
Original languageUnknown
Pages (from-to)368-374
JournalClinical And Experimental Immunology
Issue number3
Publication statusPublished - 1 Jan 2011

Cite this